Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA
Emulate signs a strategic partnership with the FDA
Amylyx announces data in Muscle & Nerve demonstrating survival benefit
Amylyx announces data in Muscle & Nerve demonstrating survival benefit
FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease
FDA starts priority review of Orphazyme’s therapy in Niemann Pick Disease
Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS
Amylyx announces New England Journal of Medicine publication demonstrating benefit of their therapy in ALS
Encouraging data about first treatment of two SOD1 ALS patients with Apic’s gene therapy published in New England Journal of Medicine
Encouraging data about first treatment of two SOD1 ALS patients with Apic’s gene therapy published in New England Journal of Medicine
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial